The 10/30 # is 57 odd million. Given all the quirks of this stock, I think the actual "real" shorts are the ones above 50 mil or so. Anything else is that crazy arb stuff; that's why there isn't the short squeeze that everyone keeps expecting. My .02 opinion.
This stock will be the *OPPOSITE* of DNDN. It refuses to blast off on promise(s), but will continue to grind higher as every "win", with concurrent real life sales/revenue, refutes the doom and gloom naysayers who point to all the negatives that have nothing to do with the actual efficacy of the drug(s).